

**IN THE CLAIMS:**

Please amend the claims to read as follows:

1-28. (Canceled)

29. (New) An antibody that binds to a polypeptide having an amino acid sequence selected from:

(a) the amino acid sequence of SEQ ID NO:17;

(b) the amino acid sequence of SEQ ID NO:19;

(c) a fragment of the amino acid sequence of SEQ ID NO:19 having activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidylcholine;

(d) the amino acid sequence of SEQ ID NO:21;

(e) a fragment of the amino acid sequence of SEQ ID NO:21 having activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidyl choline;

(f) the amino acid sequence of SEQ ID NO:23; and

(g) a fragment of the amino acid sequence of SEQ ID NO:23 having activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidylcholine.

30. (New) The antibody of claim 29, wherein the polypeptide has the amino acid sequence of SEQ ID NO:17.

31. (New) The antibody of claim 29, wherein the polypeptide has the amino acid sequence of SEQ ID NO:19.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

32. (New) The antibody of claim 29, wherein the polypeptide is a fragment of the amino acid sequence of SEQ ID NO: 19 having activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidylcholine

33. (New) The antibody of claim 29, wherein the polypeptide has the amino acid sequence of SEQ ID NO:21.

34. (New) The antibody of claim 29, wherein the polypeptide is a fragment of the amino acid sequence of SEQ ID NO:21 having activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidyl choline

35. (New) The antibody of claim 29, wherein the polypeptide has the amino acid sequence of SEQ ID NO:23.

36. (New) The antibody of claim 29, wherein the polypeptide is a fragment of the amino acid sequence of SEQ ID NO:23 having activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidylcholine

37. (New) The antibody of claim 29, wherein the antibody is a monoclonal antibody.

38. (New) The antibody of claim 29, wherein the antibody is a polyclonal antibody.

39. (New) A composition comprising the antibody of claim 29 and a pharmaceutically acceptable carrier.

40. (New) An antibody that binds a polypeptide selected from:

(a) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at

65°C in 4x SSC to the complement of the nucleic acid sequence of SEQ ID NO: 18;

(b) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at 65°C in 4x SSC to the complement of the nucleic acid sequence of SEQ ID NO: 20; and

(c) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at 65°C in 4x SSC to the complement of the nucleic acid sequence of SEQ ID NO: 22.

41. (New) The antibody of claim 40, wherein the antibody is a monoclonal antibody.

42. (New) The antibody of claim 40, wherein the antibody is a polyclonal antibody.

43. (New) A composition comprising the antibody of claim 40 and a pharmaceutically acceptable carrier.

44. (New) An antibody that binds to the polypeptide encoded by a nucleic acid molecule selected from SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, the DNA insert of the plasmid deposited with ATCC as Accession Number 69948, the DNA insert of the plasmid deposited with ATCC as Accession Number 69949, and a complement thereof.

45. (New) A composition comprising the antibody of claim 44 and a pharmaceutically acceptable carrier.

46. (New) The antibody of claim 44, wherein the antibody is a monoclonal antibody.

47. (New) The antibody of claim 44, wherein the antibody is a polyclonal antibody.

48. (New) An antibody that binds to a polypeptide encoded by a polynucleotide selected from:

(a) a first polynucleotide having the nucleotide sequence of SEQ ID NO: 1;

(b) a second polynucleotide that encodes the amino acid sequence of SEQ ID NO: 2;

(c) a third polynucleotide that hybridizes at 65°C in 4x SSC to the complement of the first or second polynucleotide, wherein the third polynucleotide encodes a polypeptide having activity in a mixed micelle assay with 1-palmitoyl-2-[<sup>14</sup>C]-arachidonyl phosphatidylcholine;

49. (New) The antibody of claim 48, wherein the antibody is a monoclonal antibody.

50. (New) The antibody of claim 48, wherein the antibody is a polyclonal antibody.

51. (New) A composition comprising the antibody of claim 48 and a pharmaceutically acceptable carrier.

52. (New) An antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO: 2.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

53. (New) The antibody of claim 52, wherein the antibody is a monoclonal antibody.

54. (New) The antibody of claim 52, wherein the antibody is a polyclonal antibody.

55. (New) A composition comprising the antibody of claim 52 and a pharmaceutically acceptable carrier.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)